EA200000427A1 - Терапевтические применения хинолиновых производных - Google Patents

Терапевтические применения хинолиновых производных

Info

Publication number
EA200000427A1
EA200000427A1 EA200000427A EA200000427A EA200000427A1 EA 200000427 A1 EA200000427 A1 EA 200000427A1 EA 200000427 A EA200000427 A EA 200000427A EA 200000427 A EA200000427 A EA 200000427A EA 200000427 A1 EA200000427 A1 EA 200000427A1
Authority
EA
Eurasian Patent Office
Prior art keywords
chemical bond
therapeutic applications
independently hydrogen
quinoline derivatives
vicinal
Prior art date
Application number
EA200000427A
Other languages
English (en)
Inventor
Заид Джэййоси
Джерард М. МакДжихан
Майкл Ф. Келли
Original Assignee
Авентис Фармасьютикалз Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Авентис Фармасьютикалз Продактс Инк. filed Critical Авентис Фармасьютикалз Продактс Инк.
Publication of EA200000427A1 publication Critical patent/EA200000427A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Способ медиирования активности PPAR-γ рецептора, включающий взаимодействие указанного PPAR-γ рецептора с соединением формулы (I), в которой A представляет O, S, (1) или химическую связь; B представляет O, S, SO, SO, NR, химическую связь; D представляет O, S, NR, (1) или химическую связь; E представляет химическую связь; a равняется 0-2; b равняется 0-1; c равняется 0-4; d равняется 0-5; e равняется 0-4; f равняется 0-5; n равняется 0-2; R представляет независимо водород; R' представляет независимо водород; Rпредставляет независимо водород; Rпредставляет (CH)-X, или два вицинальных R, взятые вместе в атомами углерода, посредством которых эти два вицинальных Rсвязаны, образуют циклоалкилен, или геминальные Rи R, взятые вместе; q равняется 0-3; X представляет водород.Международная заявка была опубликована вместе с отчетом о международном поиске.(1)
EA200000427A 1997-10-17 1998-10-16 Терапевтические применения хинолиновых производных EA200000427A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6231897P 1997-10-17 1997-10-17
US6590297P 1997-11-17 1997-11-17
PCT/US1998/021947 WO1999020275A1 (en) 1997-10-17 1998-10-16 Therapeutic uses of quinoline derivatives

Publications (1)

Publication Number Publication Date
EA200000427A1 true EA200000427A1 (ru) 2001-02-26

Family

ID=26742119

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000427A EA200000427A1 (ru) 1997-10-17 1998-10-16 Терапевтические применения хинолиновых производных

Country Status (17)

Country Link
US (1) US6376512B1 (ru)
EP (1) EP1030665A4 (ru)
JP (1) JP2001520193A (ru)
KR (1) KR20010024533A (ru)
CN (1) CN1302206A (ru)
AP (1) AP2000001786A0 (ru)
AU (1) AU9696198A (ru)
BG (1) BG104432A (ru)
BR (1) BR9814087A (ru)
CA (1) CA2306825A1 (ru)
EA (1) EA200000427A1 (ru)
HU (1) HUP0101022A1 (ru)
IL (1) IL135673A0 (ru)
NO (2) NO20001962L (ru)
OA (1) OA11371A (ru)
PL (1) PL344977A1 (ru)
WO (1) WO1999020275A1 (ru)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0010605A (pt) 1999-04-28 2002-02-13 Aventis Pharma Gmbh Derivados ácidos de di-aril como ligantes de receptores ppar
BR0010126A (pt) * 1999-04-28 2002-02-26 Aventis Pharma Gmbh Derivados de ácido tri-arìlico como ligandos receptores de ppar
US7041691B1 (en) * 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
JP2003508389A (ja) * 1999-08-27 2003-03-04 エリ リリー アンド カンパニー ビアリール−オキサ（チア）ゾール誘導体およびそのｐｐａｒモジュレーターとしての使用
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
TW200528436A (en) 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
JP2001261654A (ja) * 2000-03-21 2001-09-26 Mitsui Chemicals Inc キノリン誘導体およびそれを有効成分として含有する核内レセプター作動薬
WO2001082916A2 (en) * 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
US20030171399A1 (en) * 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
ATE433964T1 (de) 2000-12-28 2009-07-15 Takeda Pharmaceutical Alkansäurederivate, verfahren zu deren herstellung und deren verwendung
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
TWI311133B (en) 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
CZ20033394A3 (cs) 2001-06-12 2005-03-16 Wellstat Therapeutics Corporation Sloučeniny pro léčení metabolických poruch a způsob jejich přípravy
US7371777B2 (en) 2001-08-17 2008-05-13 Eisai Co., Ltd. Cyclic compound and PPAR agonist
SE0201937D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
ES2299702T3 (es) 2002-06-20 2008-06-01 Astrazeneca Ab Derivados de acido benzoico orto-sustituidos para el tratamiento de la resistencia a la insulina.
PL374860A1 (en) 2002-07-09 2005-11-14 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
MXPA06003055A (es) * 2003-09-17 2006-05-31 Novartis Ag Compuestos organicos.
JP2007536343A (ja) 2004-05-05 2007-12-13 ノボ　ノルディスク　アクティーゼルスカブ Ｐｐａｒアゴニストとしてのフェノキシ酢酸誘導体
ATE515494T1 (de) 2004-05-05 2011-07-15 High Point Pharmaceuticals Llc Neue verbindungen, deren herstellung und verwendung
CN100418532C (zh) * 2005-06-17 2008-09-17 吕志民 治疗多种疾病的NF-κB化合物抑制剂
MX2007016374A (es) 2005-06-30 2008-03-05 Novo Nordisk As Acidos fenoxiaceticos como activadores ppar delta.
EP1940767A2 (en) * 2005-09-07 2008-07-09 Plexxikon, Inc. Pparactive compounds
EA015717B1 (ru) 2005-12-22 2011-10-31 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Феноксиуксусные кислоты в качестве активаторов ppar дельта
CA2645719A1 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
JP2010502719A (ja) 2006-09-08 2010-01-28 ロード アイランド ホスピタル アルコール誘発性脳疾患の治療、予防および回復
US7645616B2 (en) 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
EP2282736B1 (en) * 2008-04-30 2015-11-11 Wellstat Therapeutics Corporation Tetrazole compounds for reducing uric acid
JP5785940B2 (ja) 2009-06-09 2015-09-30 アブラクシス バイオサイエンス， エルエルシー トリアジン誘導体類及びそれらの治療応用
CN102573484B (zh) 2009-06-09 2015-07-01 加利福尼亚资本权益有限责任公司 苄基取代的三嗪衍生物及其治疗应用
CA2765053C (en) 2009-06-09 2015-08-18 California Capital Equity, Llc Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling
CA2804593C (en) 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
US9102621B2 (en) 2010-07-12 2015-08-11 Pfizer Limited Acyl sulfonamide compounds
EP2593433B1 (en) 2010-07-12 2014-11-26 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
ES2532357T3 (es) 2010-07-12 2015-03-26 Pfizer Limited Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor
EP2593432B1 (en) 2010-07-12 2014-10-22 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
CA2804716A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
WO2015157187A1 (en) * 2014-04-06 2015-10-15 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor positive allosteric modulators (pams) and uses thereof
KR20230066341A (ko) * 2020-08-04 2023-05-15 프리시전 바이오-테라퓨틱스 에스.알.엘. 담즙산 수용체 및 류코트리엔 시스테인 수용체의 선택적 및/또는 이중 조절제로서의 퀴놀린 화합물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US4920130A (en) * 1987-11-02 1990-04-24 Rorer Pharamceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920132A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
AU683114B2 (en) * 1993-11-29 1997-10-30 Merrell Pharmaceuticals Inc. Novel benzenesulfonylimine derivatives as inhibitors of IL-1 action
DE69512495T2 (de) * 1994-10-27 2000-02-03 Yoshitomi Pharmaceutical Verfahren zur Herstellung von Chinolin-2-yl-benzoesäure
ATE262899T1 (de) * 1996-01-02 2004-04-15 Aventis Pharma Inc Substituierte (aryl, heteroaryl, arylmethyl oder heteroarylmethyl) hydroxamisaeureverbindungen

Also Published As

Publication number Publication date
NO20003107D0 (no) 2000-06-16
HUP0101022A1 (hu) 2001-10-28
OA11371A (en) 2004-01-28
WO1999020275A1 (en) 1999-04-29
BG104432A (bg) 2000-12-29
AU9696198A (en) 1999-05-10
NO20003107L (no) 2000-07-26
BR9814087A (pt) 2000-10-03
US6376512B1 (en) 2002-04-23
EP1030665A4 (en) 2002-11-27
IL135673A0 (en) 2001-05-20
NO20001962D0 (no) 2000-04-14
KR20010024533A (ko) 2001-03-26
CA2306825A1 (en) 1999-04-29
EP1030665A1 (en) 2000-08-30
AP2000001786A0 (en) 2000-04-16
JP2001520193A (ja) 2001-10-30
PL344977A1 (en) 2001-11-19
CN1302206A (zh) 2001-07-04
NO20001962L (no) 2000-06-16

Similar Documents

Publication Publication Date Title
EA200000427A1 (ru) Терапевтические применения хинолиновых производных
ATE116338T1 (de) Chemisch modifizierte proteine und deren herstellung.
NO166267C (no) Konjugat av et maalsoekende biologisk aktivt molekyl og en forbindelse inneholdende spormerkende metall, samt diagnostisk preparat inneholdende konjugatet.
ATE85608T1 (de) Verbindungen mit biologischer aktivitaet.
TR27732A (tr) Sübstitüe edilmis olan pirimidin'ler, bunlarin üretilmesine mahsus usul ve bunlarin zararlilarla mücadele maddesi ve fungisit olarak kullanilmasi.
DK0788509T3 (da) Terapeutiske peptidderivater
ES2144421T3 (es) Nuevo derivado tetrapeptidico.
BR9408167A (pt) Composto composição fungicida e método de controle de doenças em plantas
DE3483869D1 (de) Zusammensetzungen zur bekaempfung von toxaemia.
DE69330643T2 (de) Monoklonaler antikörper, welcher spezifisch an vaskularisiertes tumorendothelium bindet und verwendungen davon
NO993866D0 (no) Legemiddel mot lymfocytiske tumorer
DE69024862D1 (de) Modifiziertes, biologisch aktives Protein
BR8902929A (pt) Artigo vendavel
DE10399029I1 (de) Verwendung von Aminoadamantan-Verbindungen als Immunregulatoren.
NO983691D0 (no) Forbindelser tilhörende amidiniumfamilien, farmasöytiske preparater inneholdende disse samt anvendelse derav
DE3673657D1 (de) Oktahydroindolizine brauchbar als analgetika.
ES2041679T3 (es) Compuestos analgesicos de octohidroindolizinas 5-substituidas y productos intermedios 7-ceto.
ATE222927T1 (de) Monoklonaler antikörper gegen den tumorzytotoxischen faktor ii (tcf-ii)
KR880011328A (ko) 신규 화합물들
TH33845A (ru)
TH50173A (th) การใช้ 1-ไฮดรอกซี-2-ไพริโดนสำหรับการบำบัดการติดเชื้อที่ผิวหนัง